Trial comparisons

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=47

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT03071692-sae",
        "title": "Pemafibrate vs Placebo: serious adverse events",
        "summary": "1715 of 5264 against 1663 of 5274; risk difference 1.0 points, 95% interval -0.7 to 2.8; NCT03071692, Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)",
        "record": "/library/comparisons/NCT03071692-sae",
        "nct_id": "NCT03071692",
        "kind": "serious-adverse-events",
        "participants": 10538,
        "risk_difference": {
          "value": 0.01047743244660676,
          "lower": -0.007342160015153355,
          "upper": 0.028288351194034684
        },
        "group_1": "1,715 of 5,264",
        "group_2": "1,663 of 5,274",
        "difference": "1.0 points",
        "interval": "-0.7 to 2.8",
        "trial_title": "Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)"
      },
      {
        "id": "NCT03071692-09832b7d",
        "title": "Pemafibrate vs Placebo: Number of Participants With Occurrence of Any Component of the Primary Endpoint or All-Cause Mortality",
        "summary": "830 of 5240 against 806 of 5257; risk difference 0.5 points, 95% interval -0.9 to 1.9; NCT03071692, Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)",
        "record": "/library/comparisons/NCT03071692-09832b7d",
        "nct_id": "NCT03071692",
        "kind": "outcome",
        "participants": 10497,
        "risk_difference": {
          "value": 0.005077562885981157,
          "lower": -0.008803435970450366,
          "upper": 0.01895975940028344
        },
        "group_1": "830 of 5,240",
        "group_2": "806 of 5,257",
        "difference": "0.5 points",
        "interval": "-0.9 to 1.9",
        "trial_title": "Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=48",
  "request_id": "jh6IwxPLAQZbtR8d"
}